author-photo

Jaclyn Neely

Bristol-Myers Squibb

38

Papers

3181

Citations

Citation Trend

Filter By

Papers (26) Sort By

Journal Conference Others

A phase III, double-blind, randomized study of nivolumab (NIVO) and ipilimumab (IPI), nivo monotherapy or placebo plus transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
P-61 Relatlimab + nivolumab in patients with advanced hepatocellular carcinoma who are naive to immuno-oncology therapy but progressed on tyrosine kinase inhibitors, a phase 2, randomized, open-label study: RELATIVITY-073

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Concordance of tissue- and plasma-derived genomic profiling in CheckMate 9LA, using the FoundationOne CDx and GuardantOMNI assays.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Nivolumab Versus Sorafenib Treatment in Advanced Hepatocellular Carcinoma (CheckMate 459): A Randomised, Multicentre, Open-Label, Phase 3 Trial

2021 Social Science Research Network
Show All
- Source
- Cite
- Save
Citations (0)
Abstract 3200: Association between inflammatory gene expression signatures in blood or tumor samples and response to nivolumab in patients with SCCHN

2020 Clinical Trials
Show All
- Source
- Cite
- Save
Citations (0)
Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial.

2020 JAMA Oncology
Show All
- Source
- Cite
- Save
Citations (172)
Urelumab alone or in combination with rituximab in patients with relapsed or refractory B‐cell lymphoma

2020 American Journal of Hematology
Show All
- Source
- Cite
- Save
Citations (12)
LBA-3 CheckMate 459: Long-term (minimum follow-up 33.6 months) survival outcomes with nivolumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma

2020 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (22)
Nivolumab (NIVO) + ipilimumab (IPI) + cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (57)
MO2-11-1 [Encore]Biomarkers and clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma in CheckMate 040

2019 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (1)